(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Public ClinicalTrials.gov record NCT03465722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.
Study identification
- NCT ID
- NCT03465722
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 476 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 26, 2018 (Actual)
- Primary completion
- Mar 9, 2020 (Actual)
- Completion
- Sep 15, 2021 (Actual)
- Last update posted
- Oct 6, 2022
2018 – 2021
United States locations
- U.S. sites
- 30
- U.S. states
- 21
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Cancer Center | Phoenix | Arizona | 85054 | — |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica | California | 90404 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Centers | Boulder | Colorado | 80303 | — |
| Washington Hospital Center - Oncology and Hematology | Washington D.C. | District of Columbia | 20010 | — |
| Mayo Clinic Cancer Center | Jacksonville | Florida | 32224 | — |
| University of Miami | Miami | Florida | 33146 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northside Hospital | Atlanta | Georgia | 30341 | — |
| Northwestern Medicine | Chicago | Illinois | 60611 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| Washington University in Saint Louis | St Louis | Missouri | 63130 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| OHSU - Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| USO - Texas Oncology | Dallas | Texas | 75246 | — |
| Texas Oncology - Denton South | Denton | Texas | 76210 | — |
| University of Texas MD Anderson | Houston | Texas | 77030 | — |
| Texas Oncology - Waco | Waco | Texas | 76712 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Summit Cancer Centers | Spokane | Washington | 99216 | — |
| Medical College of Wisconsin - Froedtert Hospital | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03465722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03465722 live on ClinicalTrials.gov.